Marie Schoumacher

Marie Schoumacher

Auto-generated profile, based on publicly available information

Marie Schoumacher

Institut de Recherches Internationales Servier, 92284, Suresnes, France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
JBJordi Bertran-Alamillo
Jordi Bertran-Alamillo
VCValérie Cattan
Valérie Cattan
MSMarie Schoumacher
Marie Schoumacher
JCJordi Codony-Servat
Jordi Codony-Servat
AGAna Giménez-Capitán
Ana Giménez-Capitán
Miguel Ángel Molina-VilaMiguel Ángel Molina-Vila
Miguel Ángel Molina-Vila
Non-small cell lung cancer (NSCLC) tumors harboring mutations in EGFR ultimately relapse to therapy with EGFR tyrosine kinase inhibitors (EGFR TKIs). Here, we show that resistant cells without the p.T790M or other acquired mutations are sensitive to the Aurora B (AURKB) inhibitors barasertib and S49076. Phospho-histone H3 (pH3), a major product of AURKB, is increased in most resistant cells and treatment with AURKB inhibitors reduces the levels of pH3, triggering G1/S arrest and polyploidy. Senescence is subsequently induced in cells with acquired mutations while, in their absence, polyploidy is followed by cell death. Finally, in NSCLC patients, pH3 levels are increased after progression on EGFR TKIs and high pH3 baseline correlates with shorter survival. Our results reveal that AURKB activation is associated with acquired resistance to EGFR TKIs, and that AURKB constitutes a potential target in NSCLC progressing to anti-EGFR therapy and not carrying resistance mutations.